These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 19200825)

  • 1. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague.
    Chichester JA; Musiychuk K; Farrance CE; Mett V; Lyons J; Mett V; Yusibov V
    Vaccine; 2009 May; 27(25-26):3471-4. PubMed ID: 19200825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A plant-produced plague vaccine candidate confers protection to monkeys.
    Mett V; Lyons J; Musiychuk K; Chichester JA; Brasil T; Couch R; Sherwood R; Palmer GA; Streatfield SJ; Yusibov V
    Vaccine; 2007 Apr; 25(16):3014-7. PubMed ID: 17287055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
    Leary SE; Griffin KF; Garmory HS; Williamson ED; Titball RW
    Microb Pathog; 1997 Sep; 23(3):167-79. PubMed ID: 9281474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
    Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.
    Williamson ED; Packer PJ; Waters EL; Simpson AJ; Dyer D; Hartings J; Twenhafel N; Pitt ML
    Vaccine; 2011 Jun; 29(29-30):4771-7. PubMed ID: 21570437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270.
    Qi Z; Zhou L; Zhang Q; Ren L; Dai R; Wu B; Wang T; Zhu Z; Yang Y; Cui B; Wang Z; Wang H; Qiu Y; Guo Z; Yang R; Wang X
    Vaccine; 2010 Feb; 28(6):1655-60. PubMed ID: 20079562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.
    Jones T; Adamovicz JJ; Cyr SL; Bolt CR; Bellerose N; Pitt LM; Lowell GH; Burt DS
    Vaccine; 2006 Mar; 24(10):1625-32. PubMed ID: 16243411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
    Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
    Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
    Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
    Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.
    Powell BS; Andrews GP; Enama JT; Jendrek S; Bolt C; Worsham P; Pullen JK; Ribot W; Hines H; Smith L; Heath DG; Adamovicz JJ
    Biotechnol Prog; 2005; 21(5):1490-510. PubMed ID: 16209555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for new plague vaccines.
    Feodorova VA; Corbel MJ
    Expert Rev Vaccines; 2009 Dec; 8(12):1721-38. PubMed ID: 19943765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
    Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
    FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of
    Tong Z; Zhang X; Guo X; Wu G; Cao S; Zhang Y; Meng X; Wang T; Wang Y; Song Y; Yang R; Du Z
    mSphere; 2024 Sep; 9(9):e0033024. PubMed ID: 39158304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice.
    Little SF; Webster WM; Wilhelm H; Fisher D; Norris SL; Powell BS; Enama J; Adamovicz JJ
    Vaccine; 2010 Jan; 28(4):934-9. PubMed ID: 19925906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification and characterization of a recombinant Yersinia pestis V-F1 "Reversed" fusion protein for use as a new subunit vaccine against plague.
    Goodin JL; Powell BS; Enama JT; Raab RW; McKown RL; Coffman GL; Andrews GP
    Protein Expr Purif; 2011 Mar; 76(1):136-44. PubMed ID: 21055471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.
    Sha J; Kirtley ML; Klages C; Erova TE; Telepnev M; Ponnusamy D; Fitts EC; Baze WB; Sivasubramani SK; Lawrence WS; Patrikeev I; Peel JE; Andersson JA; Kozlova EV; Tiner BL; Peterson JW; McWilliams D; Patel S; Rothe E; Motin VL; Chopra AK
    Clin Vaccine Immunol; 2016 Jul; 23(7):586-600. PubMed ID: 27170642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory immunity is an important component of protection elicited by subunit vaccination against pneumonic plague.
    Reed DS; Martinez MJ
    Vaccine; 2006 Mar; 24(13):2283-9. PubMed ID: 16377037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates.
    Williamson ED; Flick-Smith HC; Waters E; Miller J; Hodgson I; Le Butt CS; Hill J
    Microb Pathog; 2007 Jan; 42(1):11-21. PubMed ID: 17107769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.
    Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST
    Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.